Document detail
ID

doi:10.1186/s43046-023-00177-0...

Author
Kalarani, Iyshwarya Bhaskar Sivamani, Ganesan Veerabathiran, Ramakrishnan
Langue
en
Editor

Springer

Category

Medicine & Public Health

Year

2023

listing date

5/24/2023

Keywords
aging process genetics molecular mechanisms pathogenesis thyroid carcinoma genes cancer thyroid
Metrics

Abstract

Background A malignancy of the endocrine system, one of the most common types, is thyroid cancer.

It is proven that children who receive radiation treatment for leukemia or lymphoma are at a heightened risk of thyroid cancer due to low-dose radiation exposure throughout childhood.

Several factors can increase the risk of thyroid cancer (ThyCa), such as chromosomal and genetic mutations, iodine intake, TSH levels, autoimmune thyroid disorders, estrogen, obesity, lifestyle changes, and environmental contaminants.

Objectives The study aimed to identify a specific gene as an essential candidate for thyroid cancer progression.

We might be able to focus on developing a better understanding of how thyroid cancer is inherited.

Methods The review article uses electronic databases such as PubMed, Google Scholar, Ovid MEDLINE, Embase, and Cochrane Central.

The most frequently associated genes with thyroid cancer found on PubMed were BAX, XRCC1, XRCC3, XPO5, IL-10, BRAF, RET , and K-RAS .

To perform an electronic literature search, genes derived from DisGeNET: a database of gene-disease associations, including PRKAR1A, BRAF, RET, NRAS, and KRAS, are used.

Conclusion Examining the genetics of thyroid cancer explicitly emphasizes the primary genes associated with the pathophysiology of young and older people with thyroid cancer.

Developing such gene investigations at the beginning of the thyroid cancer development process can identify better outcomes and the most aggressive thyroid cancers.

Kalarani, Iyshwarya Bhaskar,Sivamani, Ganesan,Veerabathiran, Ramakrishnan, 2023, Identification of crucial genes involved in thyroid cancer development, Springer

Document

Open

Share

Source

Articles recommended by ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw